Pyxis Oncology Bolsters Oncology Portfolio Through $16M Apexigen Acquisition
Portfolio Pulse from Benzinga Insights
Pyxis Oncology (NASDAQ:PYXS) has announced a $16 million acquisition of Apexigen (NASDAQ:APGN), expected to be completed in the second half of 2023. Pyxis Oncology will give Apexigen $16 million in stock in exchange for APGN stock.
May 24, 2023 | 4:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Apexigen is being acquired by Pyxis Oncology for $16M in stock, expected to be completed in H2 2023.
Apexigen's acquisition by Pyxis Oncology for $16M in stock could lead to a positive impact on Apexigen's stock price in the short term, as the deal is expected to be completed in the second half of 2023.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Pyxis Oncology acquires Apexigen for $16M in stock, bolstering its oncology portfolio.
The acquisition of Apexigen by Pyxis Oncology will strengthen Pyxis' oncology portfolio and potentially lead to the development of new therapeutics. This could positively impact Pyxis Oncology's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100